103 related articles for article (PubMed ID: 23418003)
1. Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007.
Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
Radiology; 2013 Jun; 267(3):807-17. PubMed ID: 23418003
[TBL] [Abstract][Full Text] [Related]
2. Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003.
Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
J Clin Oncol; 2012 Aug; 30(22):2725-30. PubMed ID: 22753917
[TBL] [Abstract][Full Text] [Related]
3. Resected colorectal cancer among Medicare beneficiaries:adoption of FDG PET.
Zafar HM; Mahmoud NN; Mitra N; Wirtalla C; Armstrong K; Groeneveld PW
Radiology; 2010 Feb; 254(2):501-8. PubMed ID: 20093522
[TBL] [Abstract][Full Text] [Related]
4. Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.
Erb CT; Su KW; Soulos PR; Tanoue LT; Gross CP
Lung Cancer; 2016 Sep; 99():200-7. PubMed ID: 27565940
[TBL] [Abstract][Full Text] [Related]
5. Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005.
Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
J Thorac Oncol; 2014 Apr; 9(4):512-8. PubMed ID: 24736074
[TBL] [Abstract][Full Text] [Related]
6. Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.
Iezzoni LI; Ngo LH; Li D; Roetzheim RG; Drews RE; McCarthy EP
Arch Phys Med Rehabil; 2008 Apr; 89(4):595-601. PubMed ID: 18373987
[TBL] [Abstract][Full Text] [Related]
7. Use of Positron Emission Tomography to Detect Recurrence and Associations With Survival in Patients With Lung and Esophageal Cancers.
Healy MA; Yin H; Reddy RM; Wong SL
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26903519
[TBL] [Abstract][Full Text] [Related]
8. Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer.
Schroeder MC; Tien YY; Wright K; Halfdanarson TR; Abu-Hejleh T; Brooks JM
Lung Cancer; 2016 May; 95():28-34. PubMed ID: 27040848
[TBL] [Abstract][Full Text] [Related]
9. Non-small cell lung cancer: prognostic importance of positive FDG PET findings in the mediastinum for patients with N0-N1 disease at pathologic analysis.
Xie L; Saynak M; Veeramachaneni NK; Fried DV; Jagtap MR; Chiu WK; Higginson DS; Lawrence MV; Khandani AH; Qaqish BF; Chen RC; Marks LB
Radiology; 2011 Oct; 261(1):226-34. PubMed ID: 21813742
[TBL] [Abstract][Full Text] [Related]
10. Pattern of Imaging after Lung Cancer Resection. 1992-2005.
Sharma G; Nishi SP; Lin YL; Kuo YF; Goodwin JS; Riall TS
Ann Am Thorac Soc; 2016 Sep; 13(9):1559-67. PubMed ID: 27243464
[TBL] [Abstract][Full Text] [Related]
11. Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant?
Tandberg DJ; Gee NG; Chino JP; D'Amico TA; Ready NE; Coleman RE; Kelsey CR
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):796-801. PubMed ID: 23870158
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
13. Ethnic Disparities in Imaging Utilization at Diagnosis of Non-Small Cell Lung Cancer.
Morgan RL; Karam SD; Bradley CJ
J Natl Cancer Inst; 2020 Dec; 112(12):1204-1212. PubMed ID: 32134453
[TBL] [Abstract][Full Text] [Related]
14. Variation in positron emission tomography use after colon cancer resection.
Bailey CE; Hu CY; You YN; Kaur H; Ernst RD; Chang GJ
J Oncol Pract; 2015 May; 11(3):e363-72. PubMed ID: 25852143
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
[TBL] [Abstract][Full Text] [Related]
16. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
18. The effect of FDG-PET on the stage distribution of non-small cell lung cancer.
Morgensztern D; Goodgame B; Baggstrom MQ; Gao F; Govindan R
J Thorac Oncol; 2008 Feb; 3(2):135-9. PubMed ID: 18303433
[TBL] [Abstract][Full Text] [Related]
19. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
20. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT
Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
